A Study of AKCEA-APOCIII-LRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy of AKCEA-APOCIII-LRx as compared to
placebo on the percent change in fasting triglycerides (TG) from baseline.